Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
N-CYANOMETHYLAMIDES AS PROTEASE INHIBITORS
Document Type and Number:
WIPO Patent Application WO/2000/055126
Kind Code:
A2
Abstract:
The present invention relates to novel $i(N)-cyanomethyl amides which are cysteine protease inhibitors, the pharmaceutically acceptable salts and $i(N)-oxides thereof, their uses as therapeutic agents and the methods of their making.

Inventors:
BRYANT CLIFFORD M (US)
PALMER JAMES T (US)
RYDZEWSKI ROBERT M (US)
SETTI EDUARDO L (US)
TIAN ZONG-QIANG (US)
VENKATRAMAN SHANKAR (US)
WANG DAN-XIONG (US)
Application Number:
PCT/US2000/006837
Publication Date:
September 21, 2000
Filing Date:
March 15, 2000
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
AXYS PHARM INC (US)
BRYANT CLIFFORD M (US)
PALMER JAMES T (US)
RYDZEWSKI ROBERT M (US)
SETTI EDUARDO L (US)
TIAN ZONG QIANG (US)
VENKATRAMAN SHANKAR (US)
WANG DAN XIONG (US)
International Classes:
A61K31/275; A61K31/277; A61K31/341; A61K31/343; A61K31/36; A61K31/381; A61K31/395; A61K31/40; A61K31/404; A61K31/4045; A61K31/4164; A61K31/4166; A61K31/417; A61K31/426; A61K31/433; A61K31/4402; A61K31/4406; A61K31/4409; A61K31/4436; A61K31/4439; A61K31/445; A61K31/4453; A61K31/4468; A61K31/454; A61K31/455; A61K31/465; A61K31/47; A61K31/495; C07D295/12; A61K31/496; A61K31/505; A61K31/535; A61K31/5375; A61K31/54; A61K31/663; A61K45/00; A61P3/10; A61P5/14; A61P9/00; A61P9/10; A61P11/00; A61P11/06; A61P17/00; A61P17/02; A61P19/02; A61P19/10; A61P21/04; A61P25/00; A61P25/28; A61P27/02; A61P29/00; A61P33/00; A61P35/00; A61P37/00; A61P37/02; A61P37/08; A61P43/00; C07C253/30; C07C255/29; C07C255/60; C07C269/06; C07C271/22; C07C273/18; C07C275/24; C07C303/40; C07C311/06; C07C311/09; C07C315/04; C07C317/50; C07C319/20; C07C323/52; C07C323/60; C07C323/62; C07D207/09; C07D207/14; C07D207/16; C07D209/06; C07D209/08; C07D209/14; C07D209/22; C07D209/26; C07D209/42; C07D209/52; C07D211/58; C07D211/60; C07D211/62; C07D213/30; C07D213/34; C07D213/40; C07D213/56; C07D213/70; C07D213/71; C07D213/75; C07D213/81; C07D213/82; C07D215/54; C07D233/24; C07D233/26; C07D233/64; C07D233/90; C07D239/28; C07D239/36; C07D277/20; C07D277/28; C07D277/30; C07D277/42; C07D277/48; C07D277/56; C07D285/135; C07D295/14; C07D295/155; C07D295/18; C07D295/20; C07D295/215; C07D307/56; C07D307/68; C07D317/68; C07D333/20; C07D333/38; C07D333/68; C07D401/12; C07D405/06; C07D405/12; C07D409/04; C07D417/04; C07D417/12; (IPC1-7): C07C271/22; C07D211/60; C07D277/48; C07D211/62; C07D209/06; C07D207/16; C07D295/14; C07D209/52; C07D213/82; A61K31/275; A61K31/395; A61P11/00; A61P17/00; A61P33/00; A61P35/00; A61P37/00; A61P25/00; A61P29/00; C07D277/30; C07D295/20; C07D417/04; C07D211/58; C07D207/14; C07D211/72; C07D417/12; C07D277/38; C07D417/06; C07C255/29
Domestic Patent References:
WO1998001133A11998-01-15
WO1998008867A11998-03-05
WO1995024382A11995-09-14
WO1995015309A11995-06-08
WO1995013069A11995-05-18
WO1990013561A11990-11-15
WO1999024460A21999-05-20
WO2000051998A12000-09-08
WO2000055124A22000-09-21
Foreign References:
EP0754454A11997-01-22
EP0536399A11993-04-14
EP0419683A11991-04-03
EP0355572A21990-02-28
Other References:
PATENT ABSTRACTS OF JAPAN vol. 013, no. 137 (C-582), 5 April 1989 (1989-04-05) & JP 63 301868 A (NIPPON KAYAKU CO LTD), 8 December 1988 (1988-12-08)
JINGRONG LI ET AL.: "Aminoacylpyrrolidine-2-nitriles: Potent and stable Inhibitors of Dipeptidyl-Peptidase IV (CD 26)" ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, vol. 323, no. 1, 1995, pages 148-154, XP000965067
SUZUE ET AL: "Hepatic agents. I. Synthesis of aminoacyl (and hydroxyacyl)aminoacetonitriles" CHEMICAL AND PHARMACEUTICAL BULLETIN,TOKYO,JP, vol. 16, no. 8, August 1968 (1968-08), pages 1417-1432, XP002108053 ISSN: 0009-2363
HANZLIK R P ET AL: "REVERSIBLE COVALENT BINDING OF PEPTIDE NITRILES TO PAPAIN" BIOCHIMICA ET BIOPHYSICA ACTA. BIOMEMBRANES,AMSTERDAM,NL, vol. 1035, no. 1, 1990, pages 62-70, XP000929836 ISSN: 0005-2736
PICKEN, PAULA P. ET AL: "Inhibition of bovine cathepsin B by amino acid-derived nitriles" BIOCHEM. SOC. TRANS., vol. 18, no. 2, 1990, page 3016 XP000929783
MCMATH, ANDREW R. ET AL: "Direct dialkylation of peptide nitriles. Application to the synthesis of 1-aminocyclopropane-1-carboxylic acid (Acc)-containing dipeptides" BULL. SOC. CHIM. FR. (1997), 134(1), 105-110 , vol. 134, no. 1, 1997, pages 105-110, XP000960770
DATABASE CHEMABS [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; YAMADA, TAKASHI ET AL: "Studies of unusual amino acids and their peptides. IX. The synthetic study of bottromycins B1 and B2" retrieved from STN Database accession no. 89:129910 XP002153760 & BULL. CHEM. SOC. JPN. (1978), 51(3), 878-83 ,
ASHWORTH D M ET AL: "4-Cyanothiazolidides as very potent, stable inhibitors of dipeptidyl peptidase IV" BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,GB,OXFORD, vol. 6, no. 22, 19 November 1996 (1996-11-19), pages 2745-2748, XP004135888 ISSN: 0960-894X
MOSER H ET AL: "130. POLY(DIPEPTAMIDINIUM)-SALZE: DEFINITION UND METHODEN ZUR PRAPARATIVEN HERSTELLUNG. POLY(DIPEPTAMIDINIUM) SALTS: DEFINITION AND METHODS OF PREPARATION" HELVETICA CHIMICA ACTA,CH,VERLAG HELVETICA CHIMICA ACTA. BASEL, vol. 69, 1986, pages 1224-1262, XP002049723 ISSN: 0018-019X
LIPSHUTZ, BRUCE H. ET AL: "Oxazolophanes as masked cyclopeptide alkaloid equivalents: cyclic peptide chemistry without peptide couplings" J. AM. CHEM. SOC., vol. 112, no. 19, 1990, pages 7032-7041, XP002153754
NORTH, MICHAEL ET AL: "Synthetic studies towards cyclic peptides. Concise synthesis of thiazoline and thiazole containing amino acids" TETRAHEDRON, vol. 46, no. 24, 1990, pages 8267-8290, XP002153755
KATRITZKY, ALAN R. ET AL: "Benzotriazole-assisted synthesis of.alpha.-(acylamino) nitriles and a conceptually novel method for peptide elongation" J. CHEM. SOC., PERKIN TRANS. 1 , no. 7, 1990, pages 1853-1857, XP002153756
THOMPSON, STEWART A. ET AL: "Carboxyl-modified amino acids and peptides as protease inhibitors" J. MED. CHEM., vol. 29, no. 1, 1986, pages 104-111, XP002153757
VARUGHESE, K. A. ET AL: "The structure and resonance Raman spectra - structure correlations for methyloxycarbonyl-L-phenylalanyl-L-alanine ethyl dithioester" CAN. J. CHEM., vol. 64, no. 8, 1986, pages 1668-1673, XP002153758
LIPSHUTZ, BRUCE H. ET AL: "Heterocycles as masked diamide/dipeptide equivalents. Formation and reactions of substituted 5-(acylamino)oxazoles as intermediates en route to the cyclopeptide alkaloids" J. AM. CHEM. SOC., vol. 105, no. 26, 1983, pages 7703-7713, XP002153759
DATABASE CHEMABS [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; LIPSHUTZ, BRUCE H. ET AL: "Chiral induction in originally racemic amino acids via 5-acyl and 5-acyloxyaminooxazoles" retrieved from STN Database accession no. 108:222080 XP002153761 & ISR. J. CHEM. (1986), 27(1), 49-55 ,
DATABASE CHEMABS [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; VARGHA, EUGEN: "Peptide derivatives. VI. N-protected di- and tripeptide nitriles" retrieved from STN Database accession no. 71:39374 XP002153762 & STUD. UNIV. BABES-BOLYAI, SER. CHEM. (1968), 13(2), 31-5 ,
GOUR-SALIN B J ET AL: "INHIBITION OF PAPAIN BY PEPTIDE NITRILES: CONVERSION OF THE NITRILEGROUP INTO OTHER FUNCTIONALITIES VIA THE PAPAIN:NITRILE THIOMIDATE ESTER ADDUCT" CANADIAN JOURNAL OF CHEMISTRY,CA,NATIONAL RESEARCH COUNCIL. OTTAWA, vol. 69, no. 8, 1991, pages 1288-1297, XP002049724 ISSN: 0008-4042
DUFOUR ET AL: "Engineering nitrile hydratase activity into a cysteine protease by a single mutation" BIOCHEMISTRY,US,AMERICAN CHEMICAL SOCIETY. EASTON, PA, vol. 34, no. 50, 1995, pages 16382-16388, XP002129204 ISSN: 0006-2960
BERGEMANN, MARCO ET AL: "Studies on the reactivity of.alpha.-cyano.alpha.-isocyano alkanoates. Versatile synthons for the assembly of imidazoles" HELV. CHIM. ACTA, vol. 82, no. 6, 1999, pages 909-918, XP002144357
Attorney, Agent or Firm:
Kezer, Wayne W. (8th Floor San Francisco, CA, US)
Liebeschuetz, Joe (8th Floor San Francisco, CA, US)
Download PDF:
Claims:
WE CLAIM:
1. A compound of Formula I: inwhich: R'is a group of Formula (a) or (b): wherein: X'and X2 independently areC (O)orCH2S (O) 2; R5 and R6 independently are hydrogen, (C16) alkyl or as defined below; R7 and R8 independently are hydrogen or (Cl 6) alkyl or as defined below; R9 and R10 independently are (i) (Cl 6) alkyl optionally substituted with cyano, halo, halosubstituted NR12R12,NR12C(O)OR12,nitro, OR12,SR12,C(O)OR12,NR12C(O)NR12R12,NR12C(NR12)NR12R12, OC(O)R12, P(O)(OR12)OR12,S(O)2NR12R12, <BR> <BR> <BR> OPXOR'OR12,NRCCOR13,S(0)R13,S(0)2R13,C(0)R13,OR14,<BR> <BR> <BR> SR14,S(0)R'4,S(0)2R14,C(0)R14,C(0)OR14,OC(0)R14,NR'15, C(O)NR14R15,S(O)2NR14R15,NR15C(O)R14,NR15C(O)OR14, NR15C(NR15)NR14R15,whereinR12ateachoccurrenceNR15C(O)NR14R15or independently is hydrogen, (C16)alkyl or halosubstituted (C13) alkyl, R13 is (Cl 6) alkyl or halosubstituted (C13)alkyl, R14 is (C3 l2) cycloalkyl (C0 6) alkyl, hetero(C512)aryl(C06)alkyl,hetero(C312)cycloalkyl(C06)alkyl,(C612)aryl(C06)alkyl, (C913) polycycloaryl (Co6) alkyl or hetero (C8 l2) polycycloaryl (C0 6) alkyl and R15 is hydrogen or (C16) alkyl, and wherein within R14 said cycloalkyl, heterocycloalkyl, aryl, heteroaryl, polycycloaryl or heterpolycycloaryl ring optionally is substituted by a group selected X3OR16,X3SR16,X3S(O)R16,X3S(O)2R16,R16, X3OC(O)R16,X3NR16R17,X3NR17C(O)R16,X3C(O)R16,X3C(O)OR16, X3S(O)2NR16R17,X3NR17C(O)NR16R17X3NR17C(O)OR16,X3C(O)NR16R17, whereinX3isabondor(C16)alkylene,R16isorX3NR17C(NR17)NR16R17, hydrogen or (Cl6) alkyl and R17 is (C3. i2) cycloalkyl (Co. 6) alkyl, hetero(C512)aryl(C06)alkyl,hetero(C312)cycloalkyl(C06)alkyl,(C612)aryl(C06)alkyl, (C912) polycycloaryl (Co6) alkyl or hetero (C8 l2) polycycloaryl (C0 6) alkyl, or (ii) a group selected from (C3, 2) cycloalkyl (C0 6) alkyl, hetero (C3 l2) cycloalkyl (C0 6) alkyl, (C912)polycycloaryl(C06)alkyland(C612)aryl(C06)alkyl,hetero(C512)aryl(C06)alkyl, hetero (C8 l2) polycycloaryl (C0 6) alkyl, wherein said cycloalkyl, heterocycloalkyl, aryl, heteroaryl, polycycloaryl or heterpolycycloaryl ring optionally is substituted by a group selected X3OR16,X3SR16,X3S(O)R16,X3S(O)2R16,R16, X3OC(O)R16,X3NR16R17,X3NR17C(O)R16,X3C(O)R16,X3C(O)OR16, X3S(O)2NR16R17,X3NR17C(O)NR16R17X3NR17C(O)OR16,X3C(O)NR16R17, <BR> <BR> or X3NR17C(NR17)NR16R17, wherein X3, R16 and R17 are as defined above; wherein within R9 and/or Rl° any alicyclic or aromatic ring system present may be substituted further by 1 to 5 radicals independently selected from (Cl 6) alkyl, (Cl 6) alkylidene, cyano, halo, halosubstituted (Cl 4) alkyl, nitro, X3NR12R12, X3NR12C(O)OR12, X3OR12,X3SR12,X3NR12C(O)NR12R12,X3NR12C(NR12)NR12R12, X3S(O)2NR12R12,X3P(O)(OR3)OR12,X3C(O)OR12,X3C(O)NR12R12, <BR> <BR> X30P(0)(OR3)OR12,X3NR12C(0)R13,XOR13,X3S(0)2R13and<BR> <BR> X3C(O)R13, wherein X3, R12 and R13 are as defined above; or R9 together with R7 and/or R10 together with R8 form trimethylene, tetramethylene or phenylene1,2dimethylene, optionally substituted with hydroxy, oxo, (C14) alkyl or methylene; or R9 and R5 together with the carbon atom to which both R9 and R5 are attached and/or Rl° and R6 together with the carbon atom to which both R10 and R6 are attached form (C38)cycloalkylene or (C3_8) heterocycloalkylene; and R11 is X4X5R18, wherein X4 iSC (O),C (O) C (O)orS (O) 2, X5 is a bond,OorNR'9, wherein R19 is hydrogen or (C16) alkyl, and R18 is (i) (Cl 6) alkyl optionally substituted by cyano, halo, halosubstituted (C13) alkyl, nitro, NR14R14, NR14C(NR14)NR14R14,OR14,SR14,NR14C(O)OR14,0NR14C(O)NR14R14, S(O)2NR14R14,P(O)(OR14)OR14,C(O)OR14,C(O)NR14R14, S(O)R15,S(O)2R15,C(O)R15,OR20,OP(O)(OR14)OR14,NR14C(O)R15, S(O)2R20,C(O)R20,C(O)OR20,C(O)NR20R21,NR20R21,SR20,S(O)R20, NR21C(O)NR20R21orNR21C(NR21)NR20R21,NR21C(O)R20,NR21C(O)OR20, wherein R14 and R15 are as defined above, R20 is (C3 l2) cycloalkyl (C0 6) alkyl, hetero(C312)cycloalkyl(C06)alkyl, hetero(C513)aryl(C06)alkyl, (C912)polycycloaryl(C06) alkyl or hetero (C8 l2) polycycloaryl (C0 6) alkyl and R21 at each occurrence independently is hydrogen or (Calkyi, or (ii) hetero(C312)cycloalkyl(C06)alkyl, (C6 l2) aryl (C06) alkyl, diphenyl (C06) alkyl, hetero (C512) aryl (Co6) alkyl, ordihetero(C56)aryl(C06)alkyl,(C912)polycycloaryl(C06)alkyl hetero (C8 l2) polycycloaryl (C0 6) alkyl wherein said cycloalkyl, heterocycloalkyl, aryl, diphenyl, heteroaryl, diheteroaryl, polycycloaryl or heterpolycycloaryl ring may be R22,X3OR22,X3SR22,X3S(O)R22,X3S(O)2R22,X3C(O)R22,substitutedby X3C(O)OR22,X3NR23C(O)R22,X3NR22R23, X3NR23C(O)NR22R23orX3NR23C(O)0R22,X3NR23S(O)2R22, X3NR23C(NR23)NR22R23, wherein X3 is as defined above, R22 is (C312)cycloalkyl(C06) alkyl, hetero (C312)cycloalkyl(C06) alkyl, (C6 12) aryl (CO 6) alkyl, hetero (C5 l2) aryl (C0 6) alkyl, (C912)polycycloaryl(C06) alkyl or hetero (C8 l2) polycycloaryl (C0 6) alkyl and R23 at each occurrence independently is hydrogen or (Cl 6) alkyl; wherein within R11 any alicyclic or aromatic ring system present may be substituted further by 1 to 5 radicals independently selected from (C16)alkyl, (C16) alkylidene, cyano, halo, halosubstituted (C14) alkyl, nitro, X3NR12C(O)NR12R12,X3NR12R12,X3NR12C(O)OR12, X3SR12,X3C(O)OR12,X3C(O)NR12R12,X3NR12C(NR12)NR12R12,X3OR12, X3OP(O)(OR3)OR12,X3NR12C(O)R13,X3S(O)2NR12R12,X3P(O)(OR3)OR12, X3S(O)R13,X3C(O)R13,whereinX3,R12andR13areasdefinedand above; R2 is hydrogen or (Cl 6) alkyl; R3 is hydrogen, (C16)alkyl or as defined below; R4 is (i) cyano,C (O)OR12 or (C16)alkyl, wherein said alkyl optionally is substituted with cyano, halo, halosubstituted (Cl 3) alkyl, nitro, NR12R12, NR12C(O)OR12, NR12C(0)NR12R12,NRCCNR'NRR12,OR12,SR12,C(0)OR12,OC(0)R12, P(O)(OR12)OR12,OP(O)(OR12)OR12,NR12C(O)R13,C(O)NR12R12,S(O)2NR12R12, <BR> <BR> <BR> <BR> <BR> C(O)R13,OR14,SR14,S(O)R14,S(O)2R14,C(O)R14,S(O)R13,S(O)2R13, <BR> NR14R15,NR15C(O)R14,NR15C(O)OR14,C(O)NR14R15,C(O)OR14,OC(O)R14, S(O)2NR14R15,NR15C(NR15)NR14R15,whereinR12,R13andR14or are as defined above, or (ii) a group selected from (C3 l2) cycloalkyl (C0 6) alkyl, hetero (C312)cycloalkyl(C06) alkyl, (C6, 2) aryl (C06) alkyl, hetero (C5 l2) aryl (C06) alkyl, (C912)polycycloaryl(C06) alkyl and hetero (C8 l2) polycycloaryl (C0 6) alkyl, wherein said cycloalkyl, heterocycloalkyl, aryl, heteroaryl, polycycloaryl or heterpolycycloaryl ring optionally is substituted by a group selected from R16, X3OR16, X3SR16, X3S(O)R16, X3C(O)OR16,X3OC(O)R16,X3NR16R17,X3NR17C(O)R16,X3S(O)2R16,X3C(O)R16, X3S(O)2NR16R17,X3NR17C(O)NR16R17orX3NR17C(O)OR16,X3C(O)NR16R17, X3,R16andR17areasdefinedabove;whereinwithinR4X3NR17C(NR17)NR16R17,wherein any alicyclic or aromatic ring system present may be substituted further by 1 to 5 radicals independently selected from (C16) alkyl, (C16) alkylidene, cyano, halo, halosubstituted X3NR12R12,X3NR12C(O)OR12,X3NR12C(O)NR12R12,(C14)alkyl,nitro, X3SR12,X3C(O)OR12,X3C(O)NR12R12,X3NR12C(NR12)NR12R12,X3OR12, X3OP(O)(OR3)OR12,X3NR12C(O)R13,X3S(O)2NR12R12,X3P(O)(OR3)OR12, X3S (O) R13, X3S(O)2R13 and X3C(O)R13, wherein X3, R12 and R13 are as defined above; or R4 taken together with R2 forms trimethylene, tetramethylene or phenylene1,2dimethylene, optionally substituted with hydroxy, oxo, (C14)alkyl or methylene; or R4 and R3 taken together with the carbon atom to which both R4 and R3 are attached form (C38)cycloalkylene or (C3_8) heterocycloalkylene, wherein said cycloalkylene or heterocycloalkylene is optionally substituted 1 to 3 radicals independently selected from (CI6) alkyl, (Cl 6) alkylidene, cyano, halo, halosubstituted (C14)alkyl, nitro, X3NR12R12, X3NR12C(NR12)NR12R12,X3OR12,X3SR12,X3NR12C(O)OR12,X3NR12C(O)NR12R12, X3S(O)2NR12R12,X3P(O)(OR3)OR12,X3C(O)OR12,X3C(O)NR12R12, X3S(O)R13,X3S(O)2R13andX3C(O)R13,X3OP(O)(OR3)OR12,X3NR12C(O)R13, wherein X3, R13and are as defined above; and the Noxide derivatives, prodrug derivatives, protected derivatives, individual isomers and mixtures of isomers; and the pharmaceutically acceptable salts thereof.
2. The compound of Claim 1 in which: R'is a group Formula (a), wherein within Formula (a): X'isC (O) ;<BR> Rus vis hydrogen, (C16) alkyl or as defined below; R'is hydrogen, (C16) alkyl or as defined below; R9 is (i) (Cl 6) alkyl optionally substituted with halosubstituted (Cl 3) alkyl, OR12, or NR12C(NR12)NR12R12, wherein R12 at each occurrence independently is hydrogen, (C,6) alkyl or halosubstituted (C13) alkyl, or (ii) (C6 l2) aryl (C0 6) alkyl, or R9 taken together with R7 forms trimethylene optionally substituted oxo, (C14) alkyl or methylene, or R9 and R5 together with the carbon atom to which both R9 and R5 are attached form (C3_8) cycloalkylene or (C3 8) heterocycloalkylene; and R11 isX4X5R18, wherein X4 isC (O), X5 is a bond,OorS (O)2 and R'8 is (i) (Cl 6) alkyl optionally substituted by C(O)NR20R21 or NR21C(O)R20, wherein R20 is (C6 l2) aryl (C0 6) alkyl and R21 at each occurrence independently is hydrogen or (C16)alkyl, or (ii) (C3 l2) cycloalkyl (C0 6) alkyl, hetero (C3 l2) cycloalkyl (C0 6) alkyl, or(C612)aryl(C06)alkyl,hetero(C513)aryl(C06)alkyl hetero (C8 l2) polycycloaryl (C0 6) alkyl, wherein said heterocycloalkyl, aryl, heteroaryl or heteropolycycoaryl ring may be substituted byR22,X3OR22,X3NR22R23, X3NR23S(O)2R22,X3S(O)2R22,X3NR17C(O)R16,X3NR23C(O)OR22, X3NR23C(O)NR22R23,whereinX3isabondor(C16)alkylene,R22X3C(O)R22or is hetero (C3, 2) cycloalkyl (C0 6) alkyl and R23 at each occurrence independently is hydrogen or (Cl 6) alkyl; wherein within R"any alicyclic or aromatic ring system present may be substituted further by 1 to 5 radicals independently selected from (C16)alkyl, (C16) alkylidene, cyano, halo, halosubstituted (C14) alkyl, nitro, X3NR12C(O)NR12R12,X3NR12R12,X3NR12C(O)OR12, X3NR12C(NR12)NR12R12,X3C(O)OR12,X3C(O)NR12R12,X3SR12, X3S(O)2NR12R12,X3NR12C(O)R13,X3OP(O)(OR3)OR12, X3S (O) R13, X3S(O)2R13 and X3C(O)R13, wherein X3 is a bond or (C16)alkylene, R12 at each occurrence independently is hydrogen, (C16)alkyl or halosubstituted R13is(C16)alkylorhalosubstituted(C13)alkyl;(C13)alkyland R3 is hydrogen, (C16)alkyl or as defined together with R4; and R4 is (i) hydrogen, cyano,C (O)OR12 or (C16)alkyl wherein said alkyl optionally is substituted withC (O) OR,OC (O) R, wherein R at each occurrence independently is hydrogen, (C,6) alkyl or halosubstituted (Calkyi, or (ii) (C610) aryl (Co3) alkyl or R4 taken together with R2 forms trimethylene or R4 and R3 taken together with the carbon atom to which both R4 and R3 are attached form (C3_8) cycloalkylene or (C3 8) heterocycloalkylene, wherein said (C3_8) cycloalkylene or (C3 8) heterocycloalkylene optionally is substituted with (Cl 6) alkyl; and the Noxide derivatives, prodrug derivatives, protected derivatives, individual isomers and mixtures of isomers; and the pharmaceutically acceptable salts thereof.
3. The compound of Claim 2 in which: R'is a group Formula (a), wherein within Formula (a): X'isC (O) ; R5 is hydrogen or as defined together with R9; R'is hydrogen; R9 is (i) (C16) alkyl or R9 and R5 together with the carbon atom to which both R'and R'are attached form (C3_8) cycloalkylene or (C3 8) heterocycloalkylene; and R11 isX4X5R18, wherein X4 isC (O) and R18 is (C612) aryl (C06) alkyl or hetero (C5 l2) aryl (C06) alkyl, wherein said aryl or heteroaryl ring may be substituted by R22,XR22,XRR23,XRCQR16,XRCXCQOR22, X3C(O)R22orX3NR23C(O)NR22R23,whereinX3NR23S(O)2R22,X3S(O)2R22, X3 is a bond or (Cl 6) alkylene, R22 is hetero (C3 l2) cycloalkyl (C0 6) alkyl and R23 at each occurrence independently is hydrogen or (C16)alkyl ; wherein within R11 any alicyclic or aromatic ring system present may be substituted further by 1 to 5 radicals independently selected from (C16) alkyl, (C16)alkylidene, cyano, halo, halosubstituted X3NR12R12,X3NR12C(O)OR12,nitro, X3OR12,X3SR12,X3NR12C(O)NR12R12,X3NR12C(NR12)NR12R12, X3S(O)2NR12R12,X3P(O)(OR3)OR12,X3C(O)OR12,X3C(O)NR12R12, XPCOXOR'PR12,XRCR13,XCOR13,XO)and X3C (O) RI3, wherein X3 is a bond or (C16)alkylene, R12 at each occurrence independently is hydrogen, (C16) alkyl or halosubstituted (C13) alkyl and R13 is (Cl 6) alkyl or halosubstituted (Cl 3) alkyl; R3 is hydrogen or as defined together with R4; and R4 is (i) hydrogen or R4 and R3 taken together with the carbon atom to which both R4 and R3 are attached form (C3 8) cycloalkylene or (C3 8) heterocycloalkylene, wherein said (C3 8) cycloalkylene or (C3_8) heterocycloalkylene optionally is substituted with (C16)alkyl ; and the Noxide derivatives, prodrug derivatives, protected derivatives, individual isomers and mixtures of isomers; and the pharmaceutically acceptable salts thereof; and the Noxide derivatives, prodrug derivatives, protected derivatives, individual isomers and mixtures of isomers; and the pharmaceutically acceptable salts thereof.
4. The compound of Claim 3 in which: R'is a group Formula (a), wherein within Formula (a): X'isC (O) ; R5 is hydrogen or as defined together with R9; R'is hydrogen; R9 is (i) (C16) alkyl or R9 and R5 together with the carbon atom to which both R9 and R5 are attached form (C38)cycloalkylene or (C3 8) heterocycloalkylene; and R11 isX4X5R18, wherein X4 isC (O) and R18 is phenyl, wherein said phenyl ring may be substituted by R22, X3OR22, X3NR22R23, X3NR17C(O)R16, X3S(O)2R22,X3C(O)R22orX3NR23C(O)OR22,X3NR23S(O)2R22, X3NR23C(O)NR22R23, wherein X3 is a bond or (Cl 6) alkylene, R22 is hetero (C3 l2) cycloalkyl (C0 6) alkyl and R23 at each occurrence independently is hydrogen or (C16)alkyl ; wherein within R11 any alicyclic or aromatic ring system present may be substituted further by 1 to 5 radicals independently selected from (C16)alkyl, (C16) alkylidene, cyano, halo, halosubstituted (C, 4) alkyl, nitro, X3NR12C(O)NR12R12,X3NR12R12,X3NR12C(O)OR12, X3SR12,X3C(O)OR12,X3C(O)NR12R12,X3NR12C(NR12)NR12R12,X3OR12, XCNRR12,XOXOROR12,X30P(0)(OR3)OR'2,X3NR12C(0)R13, andX3C(O)R13,whereinX3isabondor(C15)alkylene,X3S(O)R13,X3S(O)2R13 R12 at each occurrence independently is hydrogen, (C16)alkyl or halosubstituted (C13) alkyl and R13 is (C,6) alkyl or halosubstituted (C13)alkyl ; R3 is hydrogen or as defined together with R4; and R4 is (i) hydrogen or R4 and R3 taken together with the carbon atom to which both R4 and R3 are attached form (C3_8) cycloalkylene or (C3_8) heterocycloalkylene, wherein said (C38)cycloalkylene or (C3_8) heterocycloalkylene optionally is substituted with (CI_6) alkyl; and the Noxide derivatives, prodrug derivatives, protected derivatives, individual isomers and mixtures of isomers; and the pharmaceutically acceptable salts thereof.
5. The compound of Claim 4 which is selected from a group consisting of: N [1 (cyanomethylcarbamoyl)3methylbutyl]3 [3 (3morpholin4ylpropyl) ureido]benzamide; and N [1 (cyanomethylcarbamoyl)3methylbutyl]3 (3pyridin2ylureido) benzamide; N [ S (cyanomethylcarbamoyl)3methylbutyl]4 (3pyridin4ylmethylureido) benzamide; N[1(cyanomethylcarbamoyl)3methylbutyl]4(3piperidin4ylureido) benzamide; N [1S (dicyanomethylcarbamoyl)3methylbutyl]4morpholin4ylbenzamide; 4dimethylaminopiperidine1carboxylic acid {4 [1 (cyanomethylcarbamoyl)3 methylbutylcarbamoyl]phenyl}amide; N(1Scyanomethylcarbamoyl3methylbutyl)4(4methylpiperazin1yl)benzamide; N [1cyanomethylcarbamoyl3methylbutyl4 (2guanidinothiazol4yl) benzamide; {4 [1S (cyanomethylcarbamoyl)3methylbutylcarbamoyl]phenyl}carbamic acid 3pyridin4ylpropyl ester; and N[1 (cyanomethylcarbamoyl)3methylbutyl]4 { 3 [2 (3Himidazol4yl)ethyl] ureido}benzamide; and the Noxide derivatives, prodrug derivatives, protected derivatives, individual isomers and mixtures of isomers; and the pharmaceutically acceptable salts thereof.
6. A compound of Formula II : in which: X1X1is selected from C(O), S(O)2andP(O)2;C(S), R2independentlyarehydrogenor(C16)alkyl;R1and R3 and R4 independently are hydrogen or (C16)alkyl or R3 and R4 taken together with the carbon atom to which both R3 and R4 are attached form (C3 8) cycloalkylene; R and R6 independently are hydrogen or (Cl 6) alkyl or R5 and R6 taken together with the carbon atom to which both R5 and R6 are attached form (C3 8) cycloalkylene or (C3 8) heterocycloalkylene; and X2X3R9,whereinX3isC(O),S(O),C(S),S(O)2orP(O)2,X3isaR7is bond, O, or NR10, wherein Rl° is hydrogen or (Cl 6) alkyl, and R9 is (C3 6) cycloalkyl (C0 6) alkyl, hetero (C3 6) cycloalkyl (C06) alkyl, phenyl (C06) alkyl or hetero (C56) aryl (C06) alkyl, wherein within R9 said cycloalkyl, heterocycloalkyl, phenyl or heteroaryl is substituted by R12, X4NR11R12, X4NR11C(O)R12, X4NR11C(O)OR12, X4OR12,X4SR12,X4S(O)R12,X4NR11C(O)NR11R13,X4NR11C(NR11)NR11R12, X4C(O)OR12,X4OC(O)R12,X4C(O)NR11R12,X4S(O)2R13,X4C(O)R12, X4P(O)(OR11)OR12orX4OP(O)(OR11)OR12,X4OC(O)NR11R12,X4S(O)2NR11R12, wherein X4 is a bond or (C16)alkylene, R11 at each occurrence is hydrogen or (C, 6) alkyl and (C36)cycloalkyl(C06)alkyl,hetero(C36)cycloalkyl(C06)alkyl,phenyl(C06)alkylorR12is hetero (C56) aryl (C06) alkyl, wherein within R12 said cycloalkyi, heterocycloalkyi, phenyl or heteroaryl is substituted by R13, X4NR11R13, X4NR11C(O)R13, X4NR11C(O)OR13, XR'NR113,X4NR11C(NR11)NR11R13,XR13,XR13,XCQR13, X4C(O)OR13,X4OC(O)R13,X4C(O)NR11R13,X4S(O)2R13,X4C(O)R13, X4P(O)(OR11)OR13orX4OP(O)(OR11)OR13,X4OC(O)NR11R13,X4S(O)2NR11R13, wherein R11areand as defined above and R13 is (C36)cycloalkyl(C06)alkyl, hetero (C3_6) cycloalkyl (C06) alkyl, phenyl (C06) alkyl or hetero (C56) aryl (Co6) alkyl, wherein within R7 any alicyclic and aromatic rings present may be substituted further by 1 to 5 radicals independently selected from (Cl 6) alkyl, (C16)alkylidene, cyano, halo, halosubstituted (C14)alkyl, X5NR14C(O)OR14,X5NR14C(O)NR14R14,X5NR14R14, X5SR14,X5C(O)OR14,X5C(O)NR14R14,X5NR14C(NR14)NR14R14,X5OR14, X5OP(O)(OR5)OR14,X5NR14C(O)R15,X5S(O)3NR14R14,X5P(O)(OR5)OR14, X5S(O)R15, X5C(O)R15,whereinX5isabondor(C16)alkylene,R14atand each occurrence independently is hydrogen, (C16) alkyl or halosubstituted (Cl 3) alkyl and R15 is (Cl 6) alkyl or halosubstituted (C13) alkyl; and the Noxide derivatives, prodrug derivatives, protected derivatives, individual isomers and mixtures of isomers; and the pharmaceutically acceptable salts thereof.
7. The compound of Claim 6 in which: i X'is selected fromC (O) ; R1 and R2 both are hydrogen; R3 is isobutyl and R4 is hydrogen or R3 and R4 taken together with the carbon atom to which both R3 and R4 are attached form cyclopropylene or cyclohexylene; R5 and R6 both are hydrogen or R5 and R6 taken together with the carbon atom to which both R5 and R6 are attached form cyclohexylene or (C6) heterocycloalkylene; and R7 isXR9, wherein x2 isC (O), X3iS a bond and R9 is phenyl, wherein within R9 said phenyl is substituted by R13, X4NR11R12, X4NR11C(O)R12, X4NR11C(O)OR12, X4OR12,X4SR12,X4S(O)R12,X4NR11C(O)NR11R12,X4NR11C(NR11)NR11R13, X4C(O)OR12,X4OC(O)R12,X4C(O)NR11R12,X4S(O)2R13,X4C(O)R12, X4OC(O)NR11R12,orX4OP(O)(OR11)OR12,X4P(O)(OR11)OR12 wherein X4 is a bond or (Cl 6) alkylene, Rl'at each occurrence is hydrogen or (C16)alkyl and R12 is hetero (C3 6) cycloalkyl (C0 6) alkyl, phenyl (Co6) alkyl or hetero (C5 6) aryl (C06) alkyl, wherein within R said heterocycloalkyl, phenyl or heteroaryl is substituted by R13, X4NR11C(O)OR13,X4NR11C(O)NR11R13,X4NR11R13,X4NR11C(O)R13, X4SR13,X4S(O)R13,X4S(O)2R13,X4C(O)R13,X4NR11C(NR11)NR11R13,X4OR13, X4C(O)NR11R13,X4OC(O)NR11R13,X4S(O)2NR11R13,X4C(O)OR13,X4OC(O)R13, X4OP(O)(OR11)OR13,whereinX4andR11areasdefinedaboveX4P(O)(OR11)OR13or and R13 is (C36)cycloalkyl(C06)alkyl, hetero (C3 6) cycloalkyl (C0 6) alkyl, phenyl (Co. e) alkyl or hetero (C56) aryl (C06) alkyl, wherein within R7 any alicyclic and aromatic rings present may be substituted further by 1 to 5 radicals independently selected from (Cl 6) alkyl, (Cl 6) alkylidene, cyano, halo, halosubstituted (C14)alkyl, nitro, X5NR14R14, X5NR14C(O)OR14, X5OR14,X5SR14,X5C(O)OR14,X5NR14C(O)NR14R14,X5NR14C(NR14)NR14R14, X5P(O)(OR15)OR14,X5OP(O)(OR5)OR14,X5C(O)NR14R14,X5S(O)2NR14R14, X5NR14C (O) R15,X5S(O)R15, X5S(O)2R15 and X5C(O)R15, wherein X5 is a bond or (C16) alkylene, R14 at each occurrence independently is hydrogen, (C16) alkyl or halosubstituted (C13)alkyl and R15 is (C16)alkyl or halosubstituted (Cl 3) alkyl; and the Noxide derivatives, prodrug derivatives, protected derivatives, individual isomers and mixtures of isomers; and the pharmaceutically acceptable salts thereof.
8. The compound of Claim 7 selected from a group consisting of: N(1Scyanomethylcarbamoyl3methylbutyl) 4 (2pyrid4ylamino)thiazol4ylbenzamide; 4 [3 ( 1benzylpiperidin4yl) ureido]N ( lScyanomethylcarbamoyl 3methylbutyl) benzamide; N ( Scyanomethylcarbamoyl3methylbutyl) 4 [4 (2morpholin4ylethyl) piperazin1yl]benzamide; N(1Scyanomethylcarbamoyl3methylbutyl) 4 (2pyrid4ylthiazol4yl)benzamide; 4[3(1benzylpyrrolidin3Syl)3methylureido]N(1Scyanomethylcarbamoyl 3methylbutyl) benzamide; N(1Scyanomethylcarbamoyl3methylbutyl) 4 (4pyrid4ylpiperazin1yl)benzamide; N(1Scyanomethylcarbamoyl3methylbutyl) 4 [2 (lmethylpyridin4ylamino) thiazol4yl] benzamide; N(l Scyanomethylcarbamoyl3methylbutyl) 4 [2 (1methylpyridin4yl) thiazol4yl] benzamide; <BR> <BR> N[(S)1(Cyanomethylcarbamoyl)3methylbut3enyl]<BR> <BR> 4 [2 (pyridin4ylamino)thiazol4yl]benzamide; N(1Scyanomethylcarbamoyl3methylbutyl) 4 [2 ( 1allylpyrid4yl) thiazol4yl] benzamide; N (lSCyanomethylcarbamoyl3methylbutyl) 4 (2piperidin4ylaminothiazol4yl)benzamide; N(1Scyanomethylcarbamoyl3methylbutyl) 4(2piperazin1ylthiazol4yl)(2piperazin1ylthiazol4yl) benzamide; N(1Scyanomethylcarbamoyl3methylbutyl) 4 [2 (4methylpiperazin1yl) thiazol4yl]benzamide; N [11S (lcyanocyclopropylcarbamoyl)3methylbutyl] 4(2piperazin1ylthiazol4yl)benzamide; N [1S (1cyanocyclopropylcarbamoyl)3methylbutyl] 4 [2 (4methylpiperazin1yl) thiazol4yl] benzamide; N [1 S (1cyanocyclopropylcarbamoyl)3methylbutyl] 4 (2piperidin4ylaminothiazol4yl)benzamide; N (1cyanomethylcarbamoylcyclohexyl)4 (2piperazin1ylthiazol4yl)benzamide; N [l (Cyanomethylcarbamoyl)cyclohexyl]4 [2 (piperidin4ylamino)thiazol4yl ]benzamide; N (lRcyanomethylcarbamoyl3methylbutyl) 4 (2morpholin4ylthiazol4yl)benzamide; N (1Cyanomethylcarbamoylcyclohexyl] 4 [2 (4methylpiperazin1yl) thiazol4yl]benzamide; N [1 (4cyanotetrahydropyran4ylcarbamoyl)cyclohexyl] 4 [2 (4methylpiperazin1yl) thiazol4yl] benzamide; N (lcyanomethylcarbamoylcyclohexyl)4 (2morpholin4ylthiazol4yl)benzamide; N (1cyanomethylcarbamoylcyclohexyl) 4 (2piperazin1ylmethylthiazol4yl)benzamide; tertbutyl 4 (4 {4 [1S (1cyanocyclopropylcarbamoyl)<BR> 3methylbutylcarbamoyl] phenyl} thiazol2ylmethyl) piperazine1carboxylate;<BR> N[(S)1(1Cyanocyclopropylcarbamoyl)3methylbutyl] 4 (2piperazin1ylmethylthiazol4yl)benzamide ; and N (1 Scyanomethylcarbamoyl3methylbutyl] 4 (4morpholin4ylmethylthiazol2ylamino) benzamide; and the Noxide derivatives, prodrug derivatives, protected derivatives, individual isomers and mixtures of isomers; and the pharmaceutically acceptable salts thereof.
9. A pharmaceutical composition comprising a therapeutically effective amount of a compound of Claim 1 in combination with a pharmaceutically acceptable excipient.
10. The composition of Claim 9 which further comprises one or more active ingredient (s) selected from the group consisting of (i) a therapeutically effective amount of a bisphosphonic acid or acid ester thereof or a pharmaceutically acceptable salt thereof and (ii) a therapeutically effective amount of an estrogen receptor agonist or a pharmaceutically acceptable salt thereof.
11. The composition of Claim 10 wherein the bisphosphonic acid is selected from the group consisting of 1,1dichloromethylene1,1diphosphonic acid, 1hydroxy 3pyrrolidin1ylpropylidene1, 1bisphosphonic acid, 1hydroxyethylidene1, 1 diphosphonic acid, 1hydroxy3 (NmethylNpentylamino) propylidene1, 1bisphosphonic acid, 6amino1hydroxyhexylidene1, 1bisphosphonic acid, 3 (dimethylamino)l hydroxypropylidene1,1bisphosphonic acid, 3amino1hydroxypropylidene1, 1 bisphosphonic acid, 2pyrid2ylethylidene1,1bisphosphonic acid, 1hydroxy2 pyrid3ylethylidene1,1bisphosphonic acid, 4chlorophenylthiomethylenebisphosphonic acid and 1hydroxy2 (lHimidazol1yl) ethylidene1, 1bisphosphonic acid or acid ester thereof or a pharmaceutically acceptable salt thereof.
12. The composition of Claim 11 wherein the bisphosphonic acid is 1,1dichloromethylene1, 1diphosphonic acid or a pharmaceutically acceptable salt thereof.
13. The composition of Claim 12 which comprises 1,1dichloromethylene 1,1diphosphonate monosodium trihydrate.
14. A pharmaceutical composition comprising a therapeutically effective amount of a compound of Claim 6 in combination with a pharmaceutically acceptable excipient.
15. The composition of Claim 14 which further comprises one or more active ingredient (s) selected from the group consisting of (i) a therapeutically effective amount of a bisphosphonic acid or acid ester thereof or a pharmaceutically acceptable salt thereof and (ii) a therapeutically effective amount of an estrogen receptor agonist or a pharmaceutically acceptable salt thereof.
16. The composition of Claim 15 wherein the bisphosphonic acid is selected from the group consisting of 1,1dichloromethylene1,1diphosphonic acid, 1hydroxy 3pyrrolidin1ylpropylidene1, 1bisphosphonic acid, 1hydroxyethylidene1, 1 diphosphonic acid, 1hydroxy3(NmethylNpentylamino) propylidene1, 1bisphosphonic acid, 6amino1hydroxyhexylidene1,1bisphosphonic acid, 3 (dimethylamino)l hydroxypropylidene1,1bisphosphonic acid, 3amino1hydroxypropylidene1, 1 bisphosphonic acid, 2pyrid2ylethylidene1, 1bisphosphonic acid, 1hydroxy2 pyrid3ylethylidene1,1bisphosphonic acid, 4chlorophenylthiomethylenebisphosphonic acid and 1hydroxy2 (lHimidazol1yl) ethylidene1, 1bisphosphonic acid or acid ester thereof or a pharmaceutically acceptable salt thereof.
17. The composition of Claim 16 wherein the bisphosphonic acid is 1,1dichloromethylene1, 1diphosphonic acid or a pharmaceutically acceptable salt thereof.
18. The composition of Claim 17 which comprises 1,1dichloromethylene 1,1diphosphonate monosodium trihydrate.
19. A method of treating a disease in an animal in which cysteine protease activity contributes to the pathology and/or symptomatology of the disease, which method comprises administering to the animal a therapeutically effective amount of compound of Claim 1; or a Noxide derivative, prodrug derivative, protected derivative, individual isomer or mixture of isomers or a pharmaceutically acceptable salt thereof.
20. The method of Claim 19 wherein the disease is osteoporosis.
21. The method of Claim 20 wherein the animal is a human.
22. The method of Claim 21 wherein the human is a postmenopausal woman.
23. The method of Claim 22 wherein the cysteine protease is cathepsin K.
24. A method of treating a disease in an animal in which cysteine protease activity contributes to the pathology and/or symptomatology of the disease, which method comprises administering to the animal a therapeutically effective amount of compound of Claim 6; or a Noxide derivative, prodrug derivative, protected derivative, individual isomer or mixture of isomers or a pharmaceutically acceptable salt thereof.
25. The method of Claim 24 wherein the disease is osteoporosis.
26. The method of Claim 25 wherein the animal is a human.
27. The method of Claim 26 wherein the human is a postmenopausal woman.
28. The method of Claim 27 wherein the cysteine protease is cathepsin K.
Description:
INTERNATIONAL SEARCH REPORT Inte'ional Applieation No PC1/US 00/06837 A. CLASSIFICATION OF SUBJECT MATTER IPC 7 A61P37/00 A61P25/00 A61P29/00 C07D277/30 C07D295/20 C07D417/04 C07D211/58 C07D207/14 C07D211/72 C07D417/12 C07D277/38 C07D417/06 C07C255/29 According to International Patent Classification (IPC) or to both national classification and IPC B.FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practical, search terms used) C. DOCUMENTS CONSIDERED TO BE RELEVANT Category ° Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. X WO 95 15309 A (FERRING BV; JENKINS PAUL D 1-7 (GB); JONES D MICHAEL (GB); SZELKE MICH) 8 June 1995 (1995-06-08) page 13-page 16; table 2 X WO 95 13069 A (MORRIELLO GREGORI J 1-7 ; PATCHETT ARTHUR A (US); CHEN MENG H (US); YAN) 18 May 1995 (1995-05-18) claim 1 X WO 90 13561 A (BOOTS CO PLC) 1-7 15 November 1990 (1990-11-15) page 27 X EP 0 754 454 A (ZERIA PHARM CO LTD) 1-7 22 January 1997 (1997-01-22) page 12, line 35-line 50 ___ Further documents are listed in the continuation of box C. JY Patent family members are listed in annex. LJ L-I Special categories of cited documents : 'T'later document published after the international fiting date 'A'document defining the general state of the art which is not or priority date and not in conflict with the application but consideredto be of particular relevance invention invention 'E'earlier document but published on or after the international X document of particular relevance the claimed invention filing date cannot be considered novel or cannot be considered to 'L'document which may throw doubts on priority claim (s) or involve an inventive step when the document is taken alone which is cited to establish the publication date of another-y. document of particular relevance ; the claimed invention citation or other special reason (as specified) cannot be considered to involve an inventive step when the '0'document referring to an oraf disclosure, use, exhibition or document is combined with one or more other such docu- other means ments, such combination being obvious to a person skilled 'P'document published prior to the international filing date but in the art. later than the priority date claimed'&'document member of the same patent family Date of the actual completion of the international search Date of mailing of the international search report 24 November 2000 Name and mailing address of the ISA Authorized officer European Patent Office, P. B. 5818 Patentlaan 2 NL-2280 HV Rijswijk 6 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax : (+31-70) 340-3016 INTERNATIONAL SEARCH REPORT Intc'ional Application No PCT/US 00/06837 C. (Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT Category 0 Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. X EP 0 536 399 A (ZERIA PHARM CO LTD) 1-7 14 April 1993 (1993-04-14) page 27-page 28; table 2 X EP 0 419 683 A (JAPAN TOBACCO INC 1-7,19, ; YOSHITOMI PHARMACEUTICAL (JP)) 24 3 April 1991 (1991-04-03) page 25; table 1 X EP 0 355 572 A (BEHRINGWERKE AG) 1-7 28 February 1990 (1990-02-28) page 5 X PATENT ABSTRACTS OF JAPAN 1-7 vol. 013, no. 137 (C-582), 5 April 1989 (1989-04-05) &JP 63 301868 A (NIPPON KAYAKU CO LTD), 8 December 1988 (1988-12-08) abstract X JINGRONG LI ET AL.: 1-7 "Aminoacylpyrrolidine-2-nitriles : Potent and stable Inhibitors of Dipeptidyl-Peptidase IV (CD 26)" ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, vol. 323, no. 1,1995, pages 148-154, XP000965067 page 150-page 151 X SUZUE ET AL:"Hepatic agents. I. 1-7 Synthesis of aminoacyl (and hydroxyacyl)aminoacetonitriles" CHEMICAL AND PHARMACEUTICAL BULLETIN, TOKYO, JP, vol. 16, no. 8, August 1968 (1968-08), pages 1417-1432, XP002108053 ISSN: 0009-2363 page 1429-page 1432 X HANZLIK R P ET AL:"REVERSIBLE COVALENT 1-7 BINDING OF PEPTIDE NITRILES TO PAPAIN" BIOCHIMICA ET BIOPHYSICA ACTA. BIOMEMBRANES, AMSTERDAM, NL, vol. 1035, no. 1,1990, pages 62-70, XP000929836 ISSN: 0005-2736 page 69 X PICKEN, PAULA P. ET AL:"Inhibition of 1-7 bovine cathepsin B by amino acid-derived nitriles" BIOCHEM. SOC. TRANS., vol. 18, no. 2,1990, page 3016 XP000929783 page 316 6 INTERNATIONAL SEARCH REPORT Inte tional Application No PCI/US 00/06837 C. (Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT Category ° Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. X MCMATH, ANDREW R. ET AL:"Direct 1-7 dialkylation of peptide nitriles. Application to the synthesis of 1-aminocyclopropane-1-carboxylic acid (Acc)-containing dipeptides" BULL. SOC. CHIM. FR. (1997), 134 (1), 105-110, vol. 134, no. 1,1997, pages 105-110, XP000960770 page 106 page 108-page 109 X DATABASE CHEMABS'Online ! 1-7 CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO,US; YAMADA, TAKASHI ET AL:"Studies of unusual amino acids and their peptides. IX. The synthetic study of bottromycins B1 and B2" retrieved from STN Database accession no. 89: 129910 XP002153760 abstract &BULL. CHEM. SOC. JPN. (1978), 51 (3), 878-83, X ASHWORTH D M ET AL:"4-Cyanothiazolidides 1-7 as very potent, stable inhibitors of dipeptidyl peptidase IV" BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, GB, OXFORD, vol. 6, no. 22, 19 November 1996 (1996-11-19), pages 2745-2748, XP004135888 ISSN: 0960-894X page 2746 X MOSER H ET AL :"130. 1-7 POLY (DIPEPTAMIDINIUM)-SALZE: DEFINITION UND METHODEN ZUR PRAPARATIVEN HERSTELLUNG. POLY (DIPEPTAMIDINIUM) SALTS: DEFINITION AND METHODS OF PREPARATION" HELVETICA CHIMICA ACTA, CH, VERLAG HELVETICA CHIMICA ACTA. BASEL, vol. 69,1986, pages 1224-1262, XP002049723 ISSN : 0018-019X the whole document 6 6 INTERNATIONAL SEARCH REPORT t' ! ional Application No PCT/US 00/06837 C. (Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT Category ° Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. X LIPSHUTZ, BRUCE H. ET AL:"Oxazolophanes 1-7 as masked cyclopeptide alkaloid equivalents : cyclic peptide chemistry without peptide couplings" J. AM. CHEM. SOC., vol. 112, no. 19,1990, pages 7032-7041, XP002153754 page 7035 X NORTH, MICHAEL ET AL:"Synthetic studies 1-7 towards cyclic peptides. Concise synthesis of thiazoline and thiazole containing amino acids" TETRAHEDRON, vol. 46, no. 24,1990, pages 8267-8290, XP002153755 page 8271 X KATRITZKY, ALAN R. ET AL: 1-7 "Benzotriazole-assisted synthesis of. alpha.- (acylamino) nitriles and a conceptually novel method for peptide elongation" J. CHEM. SOC., PERKIN TRANS. 1, no. 7,1990, pages 1853-1857, XP002153756 scheme 1 page 1853 Scheme 2 page 1856 X THOMPSON, STEWART A. ET AL: 1-7 "Carboxyl-modified amino acids and peptides as protease inhibitors" J. MED. CHEM., vol. 29, no. 1,1986, pages 104-111, XP002153757 page 109 X VARUGHESE, K. A. ET AL:"The structure 1-7 and resonance Raman spectra-structure correlations for methyloxycarbonyl-L-phenylalanyl-L-alanine ethyl dithioester" CAN. J. CHEM., vol. 64, no. 8,1986, pages 1668-1673, XP002153758 page 1669 ___ 6 INTERNATIONAL SEARCH REPORT lnt, lional Application No PCT/US 00/06837 C. (Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT Category Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. X LIPSHUTZ, BRUCE H. ET AL:"Heterocycles 1-7 as masked diamide/dipeptide equivalents. Formation and reactions of substituted 5- (acylamino) oxazoles as intermediates en route to the cyclopeptide alkaloids" J. AM. CHEM. SOC., vol. 105, no. 26,1983, pages 7703-7713, XP002153759 page 7706 X DATABASE CHEMABS'Online ! 1-7 CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO,US; LIPSHUTZ, BRUCE H. ET AL:"Chiral induction in originally racemic amino acids via 5-acyl and 5-acyloxyaminooxazoles" retrieved from STN Database accession no. 108: 222080 XP002153761 abstract &ISR. J. CHEM. (1986), 27 (1), 49-55, X DATABASE CHEMABS'Online ! 1-7 CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO,US; VARGHA, EUGEN:"Peptide derivatives. VI. N-protected di-and peptide nitriles" retrieved from STN Database accession no. 71: 39374 XP002153762 abstract &STUD. UNIV. BABES-BOLYAI, SER. CHEM. (1968), 13 (2), 31-5, X GOUR-SALIN B J ET AL:"INHIBITION OF 1-7 PAPAIN BY PEPTIDE NITRILES: CONVERSION OF THE NITRILEGROUP INTO OTHER FUNCTIONALITIES VIA THE PAPAIN: NITRILE THIOMIDATE ESTER ADDUCT" CANADIAN JOURNAL OF CHEMISTRY, CA, NATIONAL RESEARCH COUNCIL. OTTAWA, vol. 69, no. 8,1991, pages 1288-1297, XP002049724 ISSN: 0008-4042 page 1289-page 1291 6 INTERNATIONAL SEARCH REPORT Inte ional Application No PC1/US 00/06837 C. (Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT Category Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. X DUFOUR ET AL:"Engineering nitrile 1-7 hydratase activity into a cysteine protease by a single mutation" BIOCHEMISTRY, US, AMERICAN CHEMICAL SOCIETY. EASTON, PA, vol. 34, no. 50,1995, pages 16382-16388, XP002129204 ISSN: 0006-2960 page 16385 P, X BERGEMANN, MARCO ET AL:"Studies on the 1-28 reactivity of. alpha.-cyano. alpha.-isocyano alkanoates. Versatile synthons for the assembly of imidazoles" HELV. CHIM. ACTA, vol. 82, no. 6,1999, pages 909-918, XP002144357 page 912 P, X WO 99 24460 A (NOVARTIS AG, 1-28 SWITZ. ; NOVARTIS-ERFINDUNGEN VERWALTUNGSGESELLSCHAFT MBH) 20 May 1999 (1999-05-20) examples 1-419 E WO 00 51998 A (BOEHRINGER INGELHEIM 1-28 PHARMA) 8 September 2000 (2000-09-08) the whole document E WO 00 55124 A (VENKATRAMAN SHANKAR; AXYS 1-28 PHARM INC (US); BUYSSE ANN M (US); PALME) 21 September 2000 (2000-09-21) the whole document 6 xnational application No. INTERNATIONAL SEARCH REPORT PCT/US 00/06837 Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet) This International Search Report has not been established in respect of certain claims under Article 17 (2) (a) for the following reasons: 1. 3 Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely : Although claims 19-28 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition. 2. ClaimsNos. : claims 1-28 (partially not searched) because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically : see FURTHER INFORMATION sheet PCT/ISA/210 3. Claims Nos. : because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4 (a). Box 11 Observations where unity of invention is lacking (Continuation of item 2 of first sheet) This International Searching Authority found multiple inventions in this international application, as follows : see additional sheet 1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims. 2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee. 3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.: 4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims ; it is covered by claims Nos.: Remark on Protest ! The additional search fees were accompanied by the applicant's protest. u v No protest accompanied the payment of additional search fees. I-J International Application No. PCTAJS 00/) 6837 FURTHER INFORMATION CONTINUED FROM PCT/ISA/210 Continuation of Box 1. 2 Claims Nos.: claims 1-28 (partially not searched) The initial phase of the search revealed a very large number of documents relevant to the issue of novelty. So many documents were retrieved that it is impossible to determine which parts of the claim (s) may be said to define subject-matter for which protection might legitimately be sought (Article 6 PCT). For these reasons it appears impossible to execute a meaningful search and/or to issue a complete search report over the whole breadth of the above mentiones claims in a far as invention 2 of the previous invitation to pay additional fees is concerned. The search and the report for above mentioned claims with respect to the content of invention 2 can only be considered complete for compounds according to the definition of invention 2 as they have been mentioned in the specific embodiments (see the examples) by chemical name and for which physico-chemical data have been provided in the description. The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1 (e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure. International Application No. PCTAJS 00 t6837 FURTHER INFORMATION CONTINUED FROM PCTiiSA/210 This International Searching Authority found multiple (groups of) inventions in this international application, as follows: 1. Claims: 1,2,4,9-13,19-23 (all partially) Compounds of formula I, wherein X1=C (O) and R4 either beeing -CN or-C (O) OR12. 2. Claims: 1, 2,5,6,9-28 (all partially) Compounds of formula I, wherein X1=C (O) ; R4= (C1-6) Alkyl (optionally substituted) or R4=H and R3=H or R4=H and R3=C (1-6) Alykl. 3. Claims: 1,5,9-13,19-23 (all partially) Compounds of formula I, wherein X1=C (O), R4 is a (poly) cycloalkyl or a (poly) cycloaryl moiety. 4. Claims: 1,2,3,4,5,6,7,8,9-28 (all partially) Compounds of formula I, wherein X1=C (O) and R4 taken together with R2 or R3 forms a cyclic structure. 5. Claims: 1, 9-13, 19-23 (all partially); 6,14-18, 24-28 (all partially) Compounds according to formula I, claim 1 with X1=CH2S02 or according to formula II claim 6 with X1 beeing either S (O) or C (S) or S (0) 2 or P (0) 2. INTERNATIONAL SEARCH REPORT Intf ional Application No Information on patentfamily members PCT/US 00/06837 Patent document Publication Patent family Publication cited in search report date member (s) date WO 9801133 A 15-01-1998 AU 3359697 A 02-02-1998 WO 9808867 A 05-03-1998 AU 713133 B 25-11-1999 AU 3868097 A 19-03-1998 BR 9712081 A 24-08-1999 CN 1235610 A 17-11-1999 EP 0933379 A 04-08-1999 WO 9524382 A 14-09-1995 AT 195933 T 15-09-2000 AU 2115695 A 25-09-1995 CA 2184691 A 14-09-1995 DE 69518631 D 05-10-2000 EP 0749418 A 27-12-1996 WO 9515309 A 08-06-1995 AU 1113395 A 19-06-1995 AU 8421998 A 12-11-1998 CA 2178066 A 08-06-1995 CN 1141033 A 22-01-1997 CZ 9601595 A 15-01-1997 EP 0731789 A 18-09-1996 FI 962315 A 05-08-1996 HU 76274 A 28-07-1997 JP 9509921 T 07-10-1997 NO 962269 A 30-07-1996 PL 314838 A 30-09-1996 US 5939560 A 17-08-1999 ZA 9409525 A 02-08-1995 WO 9513069 A 18-05-1995 US 5494919 A 27-02-1996 US 5492916 A 20-02-1996 US 5492920 A 20-02-1996 AU 1172995 A 29-05-1995 BG 100555 A 31-10-1996 BR 9408019 A 26-08-1997 CA 2175218 A 18-05-1995 CN 1174504 A 25-02-1998 CZ 9601342 A 11-12-1996 EP 0739204 A 30-10-1996 FI 961951 A 08-05-1996 HU 74733 A 28-02-1997 JP 10506091 T 16-06-1998 LV 11525 A 20-10-1996 LV 11525 B 20-02-1997 NO 961865 A 08-07-1996 PL 322706 A 16-02-1998 SK 56296 A 05-02-1997 US 5622973 A 22-04-1997 US 5721250 A 24-02-1998 US 5721251 A 24-02-1998 WO 9013561 A 15-11-1990 AT 107660 T 15-07-1994 AU 631641 B 03-12-1992 AU 5547290 A 29-11-1990 BG 60916 B 28-06-1996 CA 2056402 A 29-10-1990 CN 1047340 A 28-11-1990 DD 296960 A 19-12-1991 DE 69010199 D 28-07-1994 INTERNATIONAL SEARCH REPORT Inte ional Application No ! ntf ona! App! <cat! on No . nformation on patent family members PCT/US 00/06837 Patent document Publication Patent family Publication cited in search report date member (s) date WO 9013561 A DE 69010199 T 13-10-1994 DK 470136 T 01-08-1994 EG 19583 A 30-09-1995 EP 0470136 A 12-02-1992 ES 2055427 T 16-08-1994 GR 90100315 A, B 27-09-1991 HR 930700 A 30-06-1995 HU 58345 A 28-02-1992 HU 9500687 A 28-12-1995 IE 64351 B 26-07-1995 IL 94227 A 29-12-1994 IN 170683 A 02-05-1992 IN 173230 A 12-03-1994 JP 4506003 T 22-10-1992 LT 1645 A, B 25-07-1995 Lav 10200 A, B 20-10-1994 MX 20503 A 01-12-1993 NO 914206 A 17-12-1991 NZ 233475 A 25-10-1991 PL 166810 B 30-06-1995 PT 93921 A, B 20-11-1990 RO 112032 B 30-04-1997 RU 2074891 C 10-03-1997 US 5468480 A 21-11-1995 US 5380656 A 10-01-1995 ZA 9003228 A 28-12-1990 ZA 9003228 A 28-12-1990 EP 0754454 A 22-01-1997 JP 7228529 A 29-08-1995 AU 681251 B 21-08-1997 AU 1718195 A 04-09-1995 US 6017929 A 25-01-2000 WO 9522326 A 24-08-1995 EP 0536399 A 14-04-1993 DE 69116692 D 07-03-1996 DE 69116692 T 05-09-1996 US 5407950 A 18-04-1995 AT 133407 T 15-02-1996 AU 643300 B 11-11-1993 AU 7986691 A 31-12-1991 CA 2084204 A 08-12-1991 DK 536399 T 03-06-1996 WO 9118877 A 12-12-1991 EP 0419683 A 03-04-1991 WO 9012005 A 18-10-1990 US 5118811 A 02-06-1992 EP 0355572 A 28-02-1990 DE 3827415 A 15-02-1990 AT 87006 T 15-04-1993 AU 617507 B 28-11-1991 AU 3951589 A 15-02-1990 CA 1336080 A 27-06-1995 DE 58903791 D 22-04-1993 JP 2111788 A 24-04-1990 US 5202416 A 13-04-1993 JP 63301868 A 08-12-1988 NONE WO 9924460 A 20-05-1999 AU 1487399 A 31-05-1999 INTERNATIONAL SEARCH REPORT,". tional Application No Information on patent family members PCT/US 00/06837 Patent document Publication Patent family Publication cited in search report date member (s) date WO 9924460 A BR 9813197 A 29-08-2000 EP 1028942 A 23-08-2000 NO 20002320 A 04-07-2000 ZA 9810073 A 05-05-1999 WO 0051998 A 08-09-2000 NONE WO 0055124 A 21-09-2000 NONE